{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:35:11Z","timestamp":1770507311681,"version":"3.49.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1097\/ftd.0b013e31820fa9ad","type":"journal-article","created":{"date-parts":[[2011,3,5]],"date-time":"2011-03-05T13:13:24Z","timestamp":1299330804000},"page":"214-221","source":"Crossref","is-referenced-by-count":40,"title":["Serum Concentrations of Rufinamide in Children and Adults With Epilepsy: The Influence of Dose, Age, and Comedication"],"prefix":"10.1097","volume":"33","author":[{"given":"Theodor W","family":"May","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Boor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Rambeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"J\u00fcrgens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Korn-Merker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1535-7511.2009.01336.x","article-title":"Rufinamide: a novel broad-spectrum antiepileptic drug.","volume":"10","author":"Wheless","year":"2010","journal-title":"Epilepsy Curr"},{"key":"R2-12-20210129","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1345\/aph.1M679","article-title":"Rufinamide: a new antiepileptic medication for the treatment of seizures associated with Lennox-Gastaut syndrome.","volume":"44","author":"Wisniewski","year":"2010","journal-title":"Ann Pharmacother"},{"key":"R3-12-20210129","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/ern.10.51","article-title":"Rufinamide: a new antiepileptic drug treatment for Lennox-Gastaut syndrome.","volume":"10","author":"Ferrie","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"R4-12-20210129","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1517\/14656566.8.12.1931","article-title":"Rufinamide: a new anti-epileptic medication.","volume":"8","author":"Hakimian","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"R6-12-20210129","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1528-1167.2008.01665.x","article-title":"Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.","volume":"49","author":"Perucca","year":"2008","journal-title":"Epilepsia"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.eplepsyres.2009.12.003","article-title":"A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures.","volume":"88","author":"Elger","year":"2010","journal-title":"Epilepsy Res"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.yebeh.2010.01.005","article-title":"First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy.","volume":"17","author":"Kluger","year":"2010","journal-title":"Epilepsy Behav"},{"key":"R10-12-20210129","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.yebeh.2008.12.013","article-title":"Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience.","volume":"14","author":"Kluger","year":"2009","journal-title":"Epilepsy Behav"},{"key":"R11-12-20210129","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/j.1528-1167.2009.02160.x","article-title":"Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial.","volume":"50","author":"Brodie","year":"2009","journal-title":"Epilepsia"},{"key":"R12-12-20210129","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1177\/0883073809350508","article-title":"Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies.","volume":"24","author":"Wheless","year":"2009","journal-title":"J Child Neurol"},{"key":"R13-12-20210129","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","article-title":"Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome.","volume":"70","author":"Glauser","year":"2008","journal-title":"Neurology"},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0920-1211(00)00185-6","article-title":"Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy.","volume":"43","author":"Palhagen","year":"2001","journal-title":"Epilepsy Res"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/(SICI)1099-081X(199805)19:4<259::AID-BDD98>3.0.CO;2-V","article-title":"The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers.","volume":"19","author":"Cardot","year":"1998","journal-title":"Biopharm Drug Dispos"},{"key":"R16-12-20210129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models.","volume":"73","author":"Liang","year":"1986","journal-title":"Biometrika"},{"key":"R17-12-20210129","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1528-1157.2000.tb00218.x","article-title":"Methsuximide lowers lamotrigine blood levels: a pharmacokinetic antiepileptic drug interaction.","volume":"41","author":"Besag","year":"2000","journal-title":"Epilepsia"},{"key":"R18-12-20210129","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00007691-199904000-00007","article-title":"Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study.","volume":"21","author":"May","year":"1999","journal-title":"Ther Drug Monit"},{"key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00007691-200206000-00007","article-title":"Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication.","volume":"24","author":"May","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/00007691-200312000-00007","article-title":"Serum concentrations of levetiracetam in epileptic patients: the influence of dose and comedication.","volume":"25","author":"May","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R21-12-20210129","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/FTD.0b013e31815d0cd5","article-title":"Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication.","volume":"29","author":"May","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R22-12-20210129","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1528-1167.2007.01043.x","article-title":"Effect of age and comedication on levetiracetam pharmacokinetics and tolerability.","volume":"48","author":"Hirsch","year":"2007","journal-title":"Epilepsia"},{"key":"R23-12-20210129","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/archneur.62.9.1432","article-title":"Effect of antiepileptic drug comedication on lamotrigine clearance.","volume":"62","author":"Weintraub","year":"2005","journal-title":"Arch Neurol"},{"key":"R24-12-20210129","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.jcp.0000169418.31275.a7","article-title":"Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service.","volume":"25","author":"Reimers","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R25-12-20210129","first-page":"167","article-title":"Therapeutic drug monitoring in epileptology and psychiatry.","volume":"17","author":"Brandt","year":"2007","journal-title":"Nervenarzt"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e31820fa9ad","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:38:42Z","timestamp":1620952722000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201104000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31820fa9ad","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}